ZYBERNO
Stock Report
Updated Aug 31, 2026

Rocket Pharmaceuticals, Inc. (RCKT)

Healthcare • NASDAQ

$3.86

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
14.0/100
POOR BUSINESS
Rocket Pharmaceuticals, Inc. (RCKT) scores 14/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-5.8%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.12x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-92.4%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Rocket Pharmaceuticals, Inc. (RCKT) stock report — Zyberno Score 14/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, RCKT generated -$179.90M in Owner Earnings. Capital was deployed as follows: $169.00K invested in capital expenditures. Reinvestment rate: 4.7%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:3.86
Market Cap:$435.58M

Valuation Multiples (2)

P/B Ratio:1.18x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$260.69M

Price Action & Momentum (3)

Momentum Percentile:77 / 100
% of 52-Week High:70.8%
B. Profitability Assessment

Return Metrics (5)

ROA:-4.9%
Reinvestment Rate:4.7%
Fundamental Growth Rate (g):-4.4%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$4.99
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:289.9%
Latest Earnings Filed:2026-08-10
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:9.24x
Quick Ratio:9.24x
Cash Ratio:7.17x

Leverage Analysis (3)

Debt To Equity Ttm:0.12x
Debt-to-Equity Ratio:0.12x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-122.49x
Times Interest Earned:-122.49

Capital Structure (4)

Working Capital:258,230,000.00
Cash And Cash Equivalents:224,507,000.00
Long Term Debt:$21.27M
Net Debt:-$174.90M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$191.64M

Bottom Line Performance (3)

-$17.25M
Income Before Tax:$131.84M
Ebitda Ttm:-179,543,000.00

Operating Expenses (5)

Operating Expenses:191,643,000.00
R And D Expense:124,366,000.00
Sga Expense:67,517,000.00
Income Tax Expense:$8.62M
Interest Expense:1,892,000.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$423.10M
Current Assets:$289.55M
Ppe Net:25,099,000.00
Goodwill:39,154,000.00
Intangible Assets:$25.15M

Liability Structure (4)

Total Liabilities:54,268,000.00
Current Liabilities:31,320,000.00
Long Term Debt:$21.27M
Short Term Debt:$28.34M

Equity & Capital (3)

Equity:$368.83M
Retained Earnings:-$1.37B
Common Stock:180,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:28,341,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:7,419,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$179.62M-$179.79M

Investment Activities (2)

Investing Cash Flow:$17.45M
Capital Expenditures Ttm:169,000.00

Financing Activities (3)

Financing Cash Flow:-$1.00K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:12,100,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-0.16
-$0.17
Earnings Per Share Ttm:-$0.15

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$1.68

Book Value & Capital (2)

Book Value Per Share:$3.27
Cash Per Share:1.99

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$179.90M

Damodaran Growth Analysis (2)

Reinvestment Rate:4.7%
Fundamental Growth Rate (g):-4.4%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):-8.0%
C. Company Profile & Context

Corporate Information (6)

Symbol:RCKT
Company Name:Rocket Pharmaceuticals, Inc.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:112.84M
Shares Outstanding Basic:112.84M
Shares Outstanding Diluted:114.51M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-31 02:06:30 UTC
Data Timestamp:2026-08-18T09:20:08.758114
Scroll to Top